ClinicalTrials.gg
CompletedNCT00395512Updated Mar 27, 2013Results posted

Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Alogliptin and Pioglitazone in Diabetes Mellitus, sponsored by Takeda. Completed at 161 sites in 23 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-03-27.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
655
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.

Enrollment
8th of 39
655 · median 329
Started
2006
with 7 others
Phase 3
16 of 39
none open now
Registered
8th of 39
by date
Lead sponsor
30 of 39
Takeda

Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About alogliptin

alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.

Read the detailed description

There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% is type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes, and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected, placing an ever-increasing burden on families and the health care system.

Current pharmacologic interventions for type 2 diabetes mellitus include a diverse range of antidiabetic medications with different mechanisms of action including insulin and insulin analogues, sulfonylureas, metformin, meglitinides, thiazolidinediones, inhibitors of alpha- glucosidase, analogs of glucagon-like peptide-1, and synthetic analogues of human amylin. Despite the variety of medications, many have clinically important or potentially life-threatening side effects, restricted use in many subpopulations, concerns with long-term tolerability, and challenges related to compliance due to side effects and route of administration. All of these reasons contribute to the difficulties patients have reaching the target glycosylated hemoglobin level less than 7%.

SYR-322 (alogliptin) is a selective, orally available inhibitor of the dipeptidyl peptidase-4 enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus.

Pioglitazone (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan) that is approved for the treatment of type 2 diabetes mellitus. Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output.

As the rate of newly diagnosed cases of type 2 diabetes mellitus continues to grow, so does the need for products that will provide better glycemic control and improved safety and tolerability. Alogliptin and pioglitazone have complementary actions. Alogliptin inhibits the degradation of glucagon-like peptide-1 by inhibiting the enzyme dipeptidyl peptidase IV, thus augmenting glucose-dependent insulin secretion while pioglitazone is a peripheral and hepatic insulin sensitizer. Given the complementary mechanisms of action of alogliptin (stimulates insulin secretion) and pioglitazone (enhances insulin sensitivity), the addition of combination therapy in treatment naïve type 2 diabetes patients may potentially allow the patients to reach and maintain their glycosylated hemoglobin goal more effectively.

The aim of this study is to evaluate the effectiveness of the combination of alogliptin with pioglitazone in patients who are inadequately controlled on diet and exercise alone. Study participation is anticipated to be approximately 8.5 months.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 655 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Historical diagnosis of type 2 diabetes.
  • Failed treatment with diet and exercise for at least 2 months prior to Screening.
  • Is experiencing inadequate glycemic control as defined as glycosylated concentration between 7.5-11%, inclusive.
  • Has received any antidiabetic therapy for less than 7 days within 3 months prior to Screening.
  • Has a greater than or equal to 23 kg/m2 and less than or equal to45 kg/m2.
  • Fasting C-peptide greater than or equal to 0.8 ng per mL.
  • Regular use of other, non-excluded medications is allowed if participant is on a stable dose for at least 4 weeks prior to Screening.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Must be willing and able to monitor their blood concentrations with a home glucose monitor.

Exclusion criteria

Exclusion Criteria

  • Systolic blood pressure greater than or equal to 160 mmHg and diastolic blood pressure greater than or equal to 100 mmHg.
  • less than or equal to 12 g per dL for males and less than or equal to 10 g per dL for females.
  • greater than or equal to 2.5times the .
  • Serum creatinine greater than 2.0 mg per dL.
  • Thyroid stimulating hormone level greater than the upper limit of normal range.
  • Major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
  • Urine albumin to creatinine ratio of greater than 1000 ug per mg at Screening. If elevated, the subject may be rescreened within 1 week.
  • History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening
  • History of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
  • History of gastroparesis.
  • Has Class I to IV heart failure regardless of therapy.
  • History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
  • History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
  • History of infection with , , or .
  • History of a psychiatric disorder that will affect participant's ability to participate in the study.
  • History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.
  • Any alteration in angiotensin-II receptor inhibitors within 2 months prior to Randomization, if applicable.
  • History of alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day) or substance abuse (defined as illicit drug use) within 2 years prior to Screening.
  • Received any drug within 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within 3 months prior to Screening.
  • Previously participated in an investigational study of SYR-322.
  • Glycosylated hemoglobin concentration between 7.5-11%, inclusive, and a fasting plasma glucose less than 310 mg per dL.
  • At least 75% compliant with the single-blind placebo regimen during the run-in/stabilization period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
655 participants (actual)

Study arms

  • Experimental
    Alogliptin 25 mg QD

    Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Placebo

  • Active comparator
    Pioglitazone 30 mg QD

    Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.

    Drug: Pioglitazone · Drug: Placebo

  • Experimental
    Alogliptin 25 mg QD+ Pioglitazone 30 mg QD

    Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

  • Active comparator
    Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD

    Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

Interventions

  • Alogliptin tablets.

    Also known as: SYR-322

  • Pioglitazone tablets.

    Also known as: Actos, AD4833

  • DrugPlacebo

    Matching placebo tablets.

07

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)

    The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change From Baseline in HbA1c Over Time

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at 4 week intervals during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment and geographic region as class variables and baseline HbA1c as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16 and 20.

  2. Change From Baseline in Fasting Plasma Glucose Over Time

    The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline plasma glucose as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.

  3. Percentage of Participants With Marked Hyperglycemia

    Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL. Study week windows are defined to place hyperglycemia into visit categories.

    Time frame: Weeks 1, 2, 4, 8, 12, 16, 20 and 26.

  4. Percentage of Participants Meeting Rescue Criteria

    Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days after the first sample and analyzed by the central laboratory: 1. After more than 4 weeks of treatment but prior to the Week 8 Visit: a single fasting plasma glucose ≥310 mg/dL (≥17.5 mmol/L); 2. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥275 mg/dL (≥15.27 mmol/L); 3. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with the Baseline HbA1c.

    Time frame: Weeks 4, 8, 12, 16, 20 and 26.

  5. Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤6.5%.

    Time frame: Week 26

  6. Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7%.

    Time frame: Week 26

  7. Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7.5%.

    Time frame: Week 26

  8. Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 0.5%.

    Time frame: Baseline and Week 26

  9. Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1%.

    Time frame: Baseline and Week 26

  10. Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1.5%.

    Time frame: Baseline and Week 26

  11. Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 2.0%.

    Time frame: Baseline and Week 26

  12. Change From Baseline in Fasting Proinsulin

    Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline proinsulin as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  13. Change From Baseline in Insulin

    The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline insulin as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  14. Change From Baseline in Proinsulin/Insulin Ratio

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment and geographic region as class variables and Baseline proinsulin/insulin ratio as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  15. Change From Baseline in C-peptide Levels

    C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline C-peptide as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  16. Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance

    The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5 A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA IR as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  17. Change From Baseline in Homeostatic Model Assessment Beta Cell Function

    The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5 The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA beta cell function as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  18. Change From Baseline in Body Weight

    Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline weight as a covariate.

    Time frame: Baseline and Weeks 8, 12, 20 and 26.

  19. Change From Baseline in Total Cholesterol Level

    Change from Baseline in total cholesterol level was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline total cholesterol as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  20. Change From Baseline in Low-Density Lipoprotein Cholesterol

    Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL cholesterol as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  21. Change From Baseline in High-Density Lipoprotein Cholesterol

    Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL cholesterol as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  22. Change From Baseline in Triglyceride Levels

    Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline triglycerides as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  23. Change From Baseline in Free Fatty Acids

    Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline free fatty acid as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  24. Change From Baseline in Plasminogen Activator Inhibitor-1

    Change from Baseline in plasminogen activator inhibitor-1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline plasminogen activator inhibitor-1 as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  25. Change From Baseline in High-sensitivity C-Reactive Protein

    Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline hsCRP as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  26. Change From Baseline in Adiponectin

    Change from Baseline in adiponectin was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline adiponectin as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  27. Change From Baseline in Apolipoprotein A1

    Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline apolipoprotein A1 as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  28. Change From Baseline in Apolipoprotein A2

    Change from Baseline in apolipoprotein A2 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein A2 as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  29. Change From Baseline in Apolipoprotein B

    Change from Baseline in apolipoprotein B was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein B as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  30. Change From Baseline in Apolipoprotein C-III

    Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein C-III as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  31. Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides

    Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline NMR total triglycerides as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  32. Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles

    The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron particles as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  33. Change From Baseline in VLDL / Chylomicron Triglycerides

    The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron triglycerides as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  34. Change From Baseline in VLDL Particles

    The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL particles as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  35. Change From Baseline in Mean VLDL Particle Size

    Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean VLDL particle size as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  36. Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles

    The change from Baseline in levels of IDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline IDL particles as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  37. Change From Baseline in Low Density Lipoprotein (LDL) Particles

    The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL particles as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  38. Change From Baseline in Mean LDL Particle Size

    Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean LDL particle size as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  39. Change From Baseline in High Density Lipoprotein (HDL) Particles

    The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL particles as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

  40. Change From Baseline in Mean HDL Particle Size

    Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean HDL particle size as a covariate.

    Time frame: Baseline and Weeks 12 and 26.

08

Results

Posted Mar 27, 2013

Participant flow

Participants took part in the study at 268 investigative sites in 23 countries from 02 November 2006 to 13 February 2008.

Participant flow — Overall Study
MilestoneAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Started164163164164
Safety set164163164163
Completed126126136126
Not completed38372838
Withdrew: Adverse event3866
Withdrew: Protocol violation2367
Withdrew: Lost to follow-up2655
Withdrew: Withdrawal by subject65512
Withdrew: Physician decision6422
Withdrew: Other1100
Withdrew: Hyperglycemic rescue181046

Outcome measures

PrimaryChange From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)

The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobinAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)-0.96 ± 0.081-1.15 ± 0.083-1.71 ± 0.081-1.56 ± 0.081
Statistical analysis
  • Pioglitazone 30 mg vs Alogliptin 25 mg + Pioglitazone 30 mg · ANCOVA · p = <0.001 (ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.) · Ls mean difference: -0.56 · 95% CI -0.78 to -0.33
  • Alogliptin 25 mg vs Alogliptin 25 mg + Pioglitazone 30 mg · ANCOVA · p = <0.001 (ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.) · Ls mean difference: -0.75 · 95% CI -0.98 to -0.53
  • Pioglitazone 30 mg vs Alogliptin 12.5 mg + Pioglitazone 30 mg · ANCOVA · p = <0.001 (ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.) · Ls mean difference: -0.40 · 95% CI -0.63 to -0.18
SecondaryChange From Baseline in HbA1c Over Time

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at 4 week intervals during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment and geographic region as class variables and baseline HbA1c as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16 and 20.
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline in HbA1c Over Time
percentage of glycosylated hemoglobinAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=145, 146, 144, 150)-0.55 ± 0.043-0.30 ± 0.043-0.62 ± 0.043-0.51 ± 0.043
Week 8 (n=160, 153, 158, 158)-0.84 ± 0.058-0.72 ± 0.060-1.19 ± 0.059-1.03 ± 0.059
Week 12 (n=160, 153, 158, 158)-0.98 ± 0.070-1.04 ± 0.071-1.57 ± 0.070-1.34 ± 0.070
Week 16 (n=160, 153, 158, 158)-1.01 ± 0.080-1.17 ± 0.082-1.67 ± 0.081-1.43 ± 0.081
Week 20 (n=160, 153, 158, 158)-1.00 ± 0.077-1.20 ± 0.079-1.72 ± 0.078-1.54 ± 0.078
Statistical analysis
  • Pioglitazone 30 mg vs Alogliptin 12.5 mg + Pioglitazone 30 mg · ANCOVA · p = 0.003 · Ls mean difference: -0.33 · 95% CI -0.55 to -0.12ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.
  • Pioglitazone 30 mg vs Alogliptin 25 mg + Pioglitazone 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -0.52 · 95% CI -0.74 to -0.30ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.
  • Alogliptin 25 mg vs Alogliptin 25 mg + Pioglitazone 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -0.73 · 95% CI -0.94 to -0.51ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.
SecondaryChange From Baseline in Fasting Plasma Glucose Over Time

The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline plasma glucose as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose Over Time
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 1 (n=148, 146, 152, 151)-14.6 ± 2.93-7.3 ± 2.95-26.6 ± 2.90-23.3 ± 2.91
Week 2 (n=161, 156, 162, 159)-16.7 ± 2.87-14.2 ± 2.92-33.5 ± 2.87-30.9 ± 2.90
Week 4 (n=162, 157, 162, 161)-26.7 ± 2.72-31.9 ± 2.76-41.4 ± 2.72-39.7 ± 2.73
Week 8 (n=162, 157, 162, 162)-29.0 ± 2.80-38.0 ± 2.84-50.4 ± 2.80-48.4 ± 2.81
Week 12 (n=162, 157, 162, 162)-29.5 ± 3.01-42.4 ± 3.05-51.9 ± 3.01-49.3 ± 3.01
Week 16 (n=162, 157, 162, 162)-26.9 ± 3.11-40.6 ± 3.16-52.7 ± 3.12-46.6 ± 3.12
Week 20 (n=162, 157, 162, 162)-28.3 ± 3.06-42.0 ± 3.11-54.0 ± 3.07-47.5 ± 3.07
Week 26 (n=162, 157, 162, 162)-25.8 ± 3.26-37.3 ± 3.31-50.2 ± 3.27-48.5 ± 3.27
Statistical analysis
  • Pioglitazone 30 mg vs Alogliptin 12.5 mg + Pioglitazone 30 mg · ANCOVA · p = 0.017 · Ls mean difference: -11.2 · 95% CI -20.3 to -2.0P-value is from an ANCOVA model with treatment and geographic region as class variables and Baseline fasting plasma glucose as covariate.
  • Pioglitazone 30 mg vs Alogliptin 25 mg + Pioglitazone 30 mg · ANCOVA · p = 0.006 · Ls mean difference: -12.9 · 95% CI -22.0 to -3.8P-value is from an ANCOVA model with treatment and geographic region as class variables and Baseline fasting plasma glucose as covariate.
  • Alogliptin 25 mg vs Alogliptin 25 mg + Pioglitazone 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -24.5 · 95% CI -33.5 to -15.4P-value is from an ANCOVA model with treatment and geographic region as class variables and Baseline fasting plasma glucose as covariate.
SecondaryPercentage of Participants With Marked Hyperglycemia

Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL. Study week windows are defined to place hyperglycemia into visit categories.

Time frame:
Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Reported as:
Number · percentage of participants
Percentage of Participants With Marked Hyperglycemia
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 1 to < Week 4 (n=162, 157, 162, 161)31.531.818.528.6
Week 4 to < Week 8 (n=153, 147, 148, 147)19.015.010.814.3
Week 8 to < Week 12 (n=151, 146, 152, 146)15.211.67.28.2
Week 12 to < Week 16 (n=153, 141, 148, 139)16.39.28.17.9
Week 16 to < Week 20 (n=142, 135, 144, 131)16.214.82.86.9
Week 20 to Week 26 (n=130, 132, 143, 128)17.711.410.56.3
Overall (n=162, 157, 162, 162)44.438.225.330.9
SecondaryPercentage of Participants Meeting Rescue Criteria

Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days after the first sample and analyzed by the central laboratory: 1. After more than 4 weeks of treatment but prior to the Week 8 Visit: a single fasting plasma glucose ≥310 mg/dL (≥17.5 mmol/L); 2. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥275 mg/dL (≥15.27 mmol/L); 3. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with the Baseline HbA1c.

Time frame:
Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Rescue Criteria
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 to < Week 8 (n=160, 156, 161, 160)0000.6
Week 8 to < Week 12 (n=158, 151, 157, 153)1.3000
Week 12 to < Week 16 (n=156, 145, 153, 144)2.63.41.32.1
Week 16 to < Week 20 (n=150, 138, 149, 134)7.32.201.5
Week 20 to Week 26 (n=132, 133, 146, 130)0.81.51.40
Overall (n=160, 156, 161, 160)11.36.42.53.8
SecondaryPercentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤6.5%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%11.616.627.426.4
SecondaryPercentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%24.433.762.853.4
SecondaryPercentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7.5%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%44.555.872.072.4
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 0.5%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%66.570.689.685.3
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%43.354.675.668.1
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1.5%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.29.333.157.350.9
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 2.0%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%
percentage of participantsAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%17.719.634.133.1
SecondaryChange From Baseline in Fasting Proinsulin

Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline proinsulin as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · pmol/L
Change From Baseline in Fasting Proinsulin
pmol/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=136, 134, 135, 145)-4.9 ± 1.74-12.1 ± 1.75-16.0 ± 1.74-12.3 ± 1.68
Week 8 (n=150, 143, 146, 155)-3.7 ± 1.57-14.9 ± 1.60-18.2 ± 1.59-17.7 ± 1.54
Week 12 (n=150, 143, 147, 155)-5.9 ± 1.48-16.0 ± 1.52-18.6 ± 1.50-16.7 ± 1.46
Week 16 (n=150, 143, 147, 155)-3.4 ± 1.88-16.3 ± 1.93-16.0 ± 1.90-13.1 ± 1.85
Week 20 (n=150, 143, 147, 155)-8.1 ± 1.75-16.1 ± 1.79-19.8 ± 1.76-15.5 ± 1.72
Week 26 (n=150, 143, 147, 155)-4.8 ± 1.64-13.2 ± 1.68-18.3 ± 1.66-15.1 ± 1.61
SecondaryChange From Baseline in Insulin

The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline insulin as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · μIU/mL
Change From Baseline in Insulin
μIU/mLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=135, 133, 133, 145)0.43 ± 0.684-4.74 ± 0.689-4.67 ± 0.687-4.27 ± 0.659
Week 8 (n=150, 142, 147, 155)0.93 ± 0.811-4.41 ± 0.834-4.75 ± 0.818-4.86 ± 0.797
Week 12 (n=150, 142, 148, 155)0.29 ± 0.883-4.08 ± 0.907-2.98 ± 0.887-4.65 ± 0.867
Week 16 (n=150, 142, 148, 155)0.26 ± 0.829-4.49 ± 0.852-3.65 ± 0.833-2.73 ± 0.814
Week 20 (n=150, 142, 148, 155)-1.02 ± 0.844-4.56 ± 0.868-4.61 ± 0.848-3.06 ± 0.829
Week 26 (n=150, 142, 148, 155)-0.47 ± 0.755-4.06 ± 0.776-3.86 ± 0.759-3.72 ± 0.742
SecondaryChange From Baseline in Proinsulin/Insulin Ratio

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment and geographic region as class variables and Baseline proinsulin/insulin ratio as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · ratio
Change From Baseline in Proinsulin/Insulin Ratio
ratioAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=135, 133, 133, 145)-0.073 ± 0.0150-0.047 ± 0.0151-0.080 ± 0.0151-0.056 ± 0.0144
Week 8 (n=149, 142, 146, 155)-0.041 ± 0.0140-0.085 ± 0.0144-0.094 ± 0.0142-0.102 ± 0.0138
Week 12 (n=149, 142, 147, 155)-0.062 ± 0.0122-0.098 ± 0.0125-0.123 ± 0.0123-0.095 ± 0.0120
Week 16 (n=149, 142, 147, 155)-0.049 ± 0.0173-0.081 ± 0.0177-0.115 ± 0.0174-0.090 ± 0.0170
Week 20 (n=149, 142, 147, 155)-0.057 ± 0.0173-0.076 ± 0.0177-0.124 ± 0.0174-0.119 ± 0.0169
Week 26 (n=149, 142, 147, 155)-0.051 ± 0.0145-0.076 ± 0.0148-0.107 ± 0.0146-0.102 ± 0.0142
SecondaryChange From Baseline in C-peptide Levels

C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline C-peptide as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · ng/mL
Change From Baseline in C-peptide Levels
ng/mLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=142, 141, 141, 146)0.057 ± 0.0740-0.551 ± 0.0741-0.593 ± 0.0741-0.452 ± 0.0729
Week 8 (n=158, 150, 153, 156)0.034 ± 0.0701-0.606 ± 0.0718-0.620 ± 0.0711-0.547 ± 0.0704
Week 12 (n=158, 150, 154, 156)-0.040 ± 0.0676-0.612 ± 0.0693-0.534 ± 0.0684-0.536 ± 0.0680
Week 16 (n=158, 150, 154, 156)0.037 ± 0.0801-0.604 ± 0.0822-0.424 ± 0.0810-0.353 ± 0.0805
Week 20 (n=158, 150, 154, 156)-0.097 ± 0.0783-0.623 ± 0.0803-0.556 ± 0.0792-0.374 ± 0.0787
Week 26 (n=158, 150, 154, 156)-0.068 ± 0.0752-0.577 ± 0.0771-0.541 ± 0.0760-0.444 ± 0.0756
SecondaryChange From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance

The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5 A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA IR as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · insulin resistance
Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance
insulin resistanceAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=139, 132, 137, 143)-0.814 ± 0.5309-3.479 ± 0.5458-2.905 ± 0.5348-3.877 ± 0.5236
Week 26 (n=145, 134, 144, 148)-1.353 ± 0.3566-3.350 ± 0.3717-3.646 ± 0.3579-3.508 ± 0.3532
SecondaryChange From Baseline in Homeostatic Model Assessment Beta Cell Function

The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5 The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA beta cell function as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · percentage beta cell function
Change From Baseline in Homeostatic Model Assessment Beta Cell Function
percentage beta cell functionAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n= 139, 132, 137, 143)15.133 ± 4.278717.328 ± 4.386830.266 ± 4.300622.134 ± 4.2098
Week 26 (n=145, 134, 144, 148)10.472 ± 8.530617.500 ± 8.871839.153 ± 8.545524.887 ± 8.4285
SecondaryChange From Baseline in Body Weight

Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline weight as a covariate.

Time frame:
Baseline and Weeks 8, 12, 20 and 26.
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight
kgAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 8 (n=155, 146, 152, 151)-0.34 ± 0.1840.58 ± 0.1890.82 ± 0.1850.70 ± 0.186
Week 12 (n=159, 147, 155, 154)-0.78 ± 0.2270.96 ± 0.2361.35 ± 0.2301.22 ± 0.230
Week 20 (n=159, 147, 155, 154)-0.47 ± 0.2651.56 ± 0.2752.36 ± 0.2681.86 ± 0.269
Week 26 (n=159, 147, 155, 154)-0.29 ± 0.2912.19 ± 0.3023.14 ± 0.2952.51 ± 0.296
SecondaryChange From Baseline in Total Cholesterol Level

Change from Baseline in total cholesterol level was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline total cholesterol as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Total Cholesterol Level
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=146, 144, 142, 149)-8.5 ± 2.220.9 ± 2.23-0.4 ± 2.25-5.3 ± 2.20
Week 8 (n=160, 151, 154, 158)-5.4 ± 2.307.2 ± 2.37-0.3 ± 2.34-1.2 ± 2.31
Week 12 (n=160, 151, 155, 158)-4.0 ± 2.434.9 ± 2.51-0.6 ± 2.474.4 ± 2.45
Week 16 (n=160, 151, 155, 158)-4.3 ± 2.424.6 ± 2.493.8 ± 2.464.7 ± 2.44
Week 20 (n=160, 151, 155, 158)-2.9 ± 2.674.5 ± 2.75-0.3 ± 2.71-0.6 ± 2.69
Week 26 (n=160, 151, 155, 158)-0.5 ± 2.616.5 ± 2.683.7 ± 2.654.0 ± 2.62
SecondaryChange From Baseline in Low-Density Lipoprotein Cholesterol

Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL cholesterol as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Low-Density Lipoprotein Cholesterol
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=137, 130, 135, 142)-3.5 ± 1.882.8 ± 1.932.2 ± 1.89-2.8 ± 1.85
Week 8 (n=152, 139, 147, 153)-0.5 ± 1.967.6 ± 2.052.6 ± 1.991.3 ± 1.95
Week 12 (n=154, 140, 148, 154)0.8 ± 2.025.8 ± 2.121.4 ± 2.063.9 ± 2.02
Week 16 (n=154, 140, 148, 154)1.8 ± 2.226.6 ± 2.335.3 ± 2.274.6 ± 2.22
Week 20 (n=154, 140, 148, 154)0.9 ± 2.277.4 ± 2.382.1 ± 2.320.5 ± 2.27
Week 26 (n=154, 140, 148, 154)2.0 ± 2.228.1 ± 2.334.6 ± 2.273.8 ± 2.22
SecondaryChange From Baseline in High-Density Lipoprotein Cholesterol

Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL cholesterol as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in High-Density Lipoprotein Cholesterol
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=146, 144, 142, 149)-0.2 ± 0.543.0 ± 0.543.8 ± 0.553.0 ± 0.54
Week 8 (n=160, 151, 154, 158)0.5 ± 0.564.7 ± 0.585.0 ± 0.574.8 ± 0.57
Week 12 (n=160, 151, 155, 158)0.9 ± 0.646.0 ± 0.666.4 ± 0.656.5 ± 0.65
Week 16 (n=160, 151, 155, 158)0.9 ± 0.575.2 ± 0.586.0 ± 0.585.9 ± 0.57
Week 20 (n=160, 151, 155, 158)0.5 ± 0.594.7 ± 0.605.6 ± 0.605.6 ± 0.59
Week 26 (n=160, 151, 155, 158)0.8 ± 0.645.7 ± 0.666.2 ± 0.656.2 ± 0.64
SecondaryChange From Baseline in Triglyceride Levels

Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline triglycerides as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Triglyceride Levels
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 4 (n=146, 144, 142, 149)-28.2 ± 8.60-43.2 ± 8.63-51.7 ± 8.70-32.1 ± 8.51
Week 8 (n=160, 151, 154, 158)-34.8 ± 6.51-38.2 ± 6.69-61.6 ± 6.63-51.9 ± 6.56
Week 12 (n=160, 151, 155, 158)-36.4 ± 6.90-47.9 ± 7.09-64.3 ± 7.00-45.4 ± 6.95
Week 16 (n=160, 151, 155, 158)-44.5 ± 5.74-48.3 ± 5.90-54.6 ± 5.82-43.9 ± 5.78
Week 20 (n=160, 151, 155, 158)-29.9 ± 7.35-46.6 ± 7.56-59.3 ± 7.46-46.5 ± 7.41
Week 26 (n=160, 151, 155, 158)-24.7 ± 6.83-46.6 ± 7.02-56.2 ± 6.92-43.1 ± 6.88
SecondaryChange From Baseline in Free Fatty Acids

Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline free fatty acid as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mmol/L
Change From Baseline in Free Fatty Acids
mmol/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=148, 136, 140, 147)-0.0404 ± 0.01643-0.0990 ± 0.01716-0.1061 ± 0.01690-0.0805 ± 0.01650
Week 26 (n=154, 136, 147, 150)-0.0429 ± 0.01624-0.0680 ± 0.01729-0.0881 ± 0.01662-0.1013 ± 0.01647
SecondaryChange From Baseline in Plasminogen Activator Inhibitor-1

Change from Baseline in plasminogen activator inhibitor-1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline plasminogen activator inhibitor-1 as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · ng/mL
Change From Baseline in Plasminogen Activator Inhibitor-1
ng/mLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=136, 127, 131, 133)-1.58 ± 2.815-4.23 ± 2.909-9.63 ± 2.870-11.87 ± 2.849
Week 26 (n=145, 129, 142, 137)1.71 ± 3.151-5.45 ± 3.341-7.14 ± 3.189-8.38 ± 3.246
SecondaryChange From Baseline in High-sensitivity C-Reactive Protein

Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline hsCRP as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/L
Change From Baseline in High-sensitivity C-Reactive Protein
mg/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=147, 134, 138, 146)-0.4497 ± 0.41497-1.7446 ± 0.43493-1.5346 ± 0.42831-2.2771 ± 0.41646
Week 26 (n=153, 135, 144, 149)-0.1851 ± 0.42623-1.0391 ± 0.45388-1.9763 ± 0.43925-1.9796 ± 0.43182
SecondaryChange From Baseline in Adiponectin

Change from Baseline in adiponectin was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline adiponectin as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · μg/mL
Change From Baseline in Adiponectin
μg/mLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=148, 137, 141, 147)-0.28 ± 0.5606.35 ± 0.5828.10 ± 0.5757.50 ± 0.562
Week 26 (n=154, 137, 147, 149)-0.09 ± 0.5706.90 ± 0.6056.85 ± 0.5867.16 ± 0.581
SecondaryChange From Baseline in Apolipoprotein A1

Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline apolipoprotein A1 as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein A1
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=140, 138, 137, 144)-1.6 ± 1.572.3 ± 1.581.0 ± 1.591.7 ± 1.55
Week 26 (n=149, 139, 146, 146)-4.5 ± 1.591.2 ± 1.640.8 ± 1.601.6 ± 1.60
SecondaryChange From Baseline in Apolipoprotein A2

Change from Baseline in apolipoprotein A2 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein A2 as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein A2
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=140, 138, 137, 144)-0.1 ± 0.413.4 ± 0.412.8 ± 0.413.2 ± 0.40
Week 26 (n=149, 139, 146, 146)-0.3 ± 0.412.9 ± 0.432.5 ± 0.422.6 ± 0.42
SecondaryChange From Baseline in Apolipoprotein B

Change from Baseline in apolipoprotein B was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein B as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein B
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=140, 138, 137, 143)-4.0 ± 1.76-5.0 ± 1.78-9.8 ± 1.78-5.9 ± 1.74
Week 26 (n=149, 139, 146, 146)-2.5 ± 1.84-3.7 ± 1.91-7.9 ± 1.86-6.4 ± 1.86
SecondaryChange From Baseline in Apolipoprotein C-III

Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein C-III as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein C-III
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=140, 138, 138, 144)-0.5 ± 0.30-0.3 ± 0.30-0.8 ± 0.30-0.3 ± 0.30
Week 26 (n=149, 139, 147, 146)-0.4 ± 0.28-0.2 ± 0.29-0.3 ± 0.28-0.4 ± 0.28
SecondaryChange From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides

Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline NMR total triglycerides as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=139, 132, 132, 141)-14.9 ± 6.36-25.0 ± 6.52-39.7 ± 6.52-23.7 ± 6.32
Week 26 (n=147, 133, 141, 147)-7.6 ± 5.82-20.2 ± 6.11-28.8 ± 5.94-22.6 ± 5.82
SecondaryChange From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles

The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron particles as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · nmol/L
Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles
nmol/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Total Particles - Week 12 (n=139, 132, 132, 141)-6.59 ± 2.6000.70 ± 2.663-9.63 ± 2.664-2.67 ± 2.578
Total Particles - Week 26 (n=147, 133, 141, 147)-4.97 ± 2.8314.94 ± 2.976-0.73 ± 2.888-1.17 ± 2.828
Large Particles - Week 12 (n=139, 132, 132, 141)-0.94 ± 0.511-1.83 ± 0.525-2.63 ± 0.525-2.06 ± 0.508
Large Particles - Week 26 (n=147, 133, 141, 147)-0.18 ± 0.480-1.96 ± 0.505-2.37 ± 0.490-2.11 ± 0.480
SecondaryChange From Baseline in VLDL / Chylomicron Triglycerides

The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron triglycerides as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in VLDL / Chylomicron Triglycerides
mg/dLAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=139, 132, 132, 141)-14.4 ± 6.34-25.6 ± 6.50-39.5 ± 6.50-24.2 ± 6.30
Week 26 (n=147, 133, 141, 147)-8.2 ± 5.79-22.0 ± 6.08-29.7 ± 5.90-23.3 ± 5.79
SecondaryChange From Baseline in VLDL Particles

The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL particles as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · nmol/L
Change From Baseline in VLDL Particles
nmol/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Medium Particles - Week 12 (n=139, 132, 132, 141)-3.20 ± 1.639-2.30 ± 1.678-8.52 ± 1.679-4.69 ± 1.625
Medium Particles - Week 26 (n=147, 133, 141, 147)-0.23 ± 1.784-0.39 ± 1.874-3.76 ± 1.819-3.58 ± 1.782
Small Particles - Week 12 (n=139, 132, 132, 141)-1.74 ± 1.6174.77 ± 1.6621.18 ± 1.6603.71 ± 1.607
Small Particles - Week 26 (n=147, 133, 141, 147)-4.11 ± 1.7107.16 ± 1.8025.22 ± 1.7464.36 ± 1.711
SecondaryChange From Baseline in Mean VLDL Particle Size

Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean VLDL particle size as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · nm
Change From Baseline in Mean VLDL Particle Size
nmAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=139, 132, 132, 141)-0.97 ± 0.668-3.97 ± 0.688-2.92 ± 0.687-2.85 ± 0.665
Week 26 (n=147, 133, 141, 147)0.30 ± 0.607-3.71 ± 0.640-4.21 ± 0.620-2.80 ± 0.607
SecondaryChange From Baseline in Intermediate Density Lipoprotein (IDL) Particles

The change from Baseline in levels of IDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline IDL particles as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · nmol/L
Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles
nmol/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=139, 132, 132, 141)-2.9 ± 3.63-1.0 ± 3.72-2.9 ± 3.73-4.0 ± 3.61
Week 26 (n=147, 133, 141, 147)0.5 ± 3.682.1 ± 3.86-1.0 ± 3.75-5.8 ± 3.68
SecondaryChange From Baseline in Low Density Lipoprotein (LDL) Particles

The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL particles as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · nmol/L
Change From Baseline in Low Density Lipoprotein (LDL) Particles
nmol/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Total Particles - Week 12 (n=139, 132, 132, 141)-11.9 ± 28.57-104.1 ± 29.34-207.0 ± 29.33-181.8 ± 28.40
Total Particles - Week 26 (n=147, 133, 141, 147)60.9 ± 30.67-75.6 ± 32.29-169.9 ± 31.31-177.1 ± 30.68
Large Particles - Week 12 (n=139, 132, 132, 141)15.3 ± 15.1698.8 ± 15.52129.4 ± 15.54142.1 ± 15.05
Large Particles - Week 26 (n=147, 133, 141, 147)2.6 ± 15.32120.4 ± 16.10146.6 ± 15.63155.5 ± 15.33
Medium-Small - Week 12 (n=139, 132, 132, 141)-6.2 ± 6.25-41.4 ± 6.41-65.8 ± 6.41-65.8 ± 6.20
Medium-Small - Week 26 (n=147, 133, 141, 147)9.9 ± 6.42-40.1 ± 6.75-63.0 ± 6.55-66.6 ± 6.41
Total Small - Week 12 (n=139, 132, 132, 141)-27.8 ± 31.91-200.3 ± 32.71-331.2 ± 32.73-320.0 ± 31.66
Total Small - Week 26 (n=147, 133, 141, 147)54.5 ± 33.34-195.8 ± 35.04-313.8 ± 34.01-327.4 ± 33.30
Very Small - Week 12 (n=139, 132, 132, 141)-20.9 ± 26.22-159.2 ± 26.88-265.7 ± 26.90-254.2 ± 26.02
Very Small - Week 26 (n=147, 133, 141, 147)45.1 ± 27.44-156.0 ± 28.83-250.9 ± 27.98-260.8 ± 27.40
SecondaryChange From Baseline in Mean LDL Particle Size

Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean LDL particle size as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · nm
Change From Baseline in Mean LDL Particle Size
nmAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=139, 132, 132, 141)0.09 ± 0.0510.44 ± 0.0530.63 ± 0.0530.58 ± 0.051
Week 26 (n=147, 133, 141, 147)-0.02 ± 0.0520.44 ± 0.0540.65 ± 0.0530.61 ± 0.052
SecondaryChange From Baseline in High Density Lipoprotein (HDL) Particles

The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL particles as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · µmol/L
Change From Baseline in High Density Lipoprotein (HDL) Particles
µmol/LAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Total Particles - Week 12 (n=139, 132, 132, 141)0.18 ± 0.3500.92 ± 0.3590.11 ± 0.3590.54 ± 0.348
Total Particles - Week 26 (n=147, 133, 141, 147)0.81 ± 0.3591.67 ± 0.3771.01 ± 0.3671.03 ± 0.359
Large Particles - Week 12 (n=139, 132, 132, 141)0.07 ± 0.1950.99 ± 0.2000.98 ± 0.2001.31 ± 0.193
Large Particles - Week 26 (n=147, 133, 141, 147)-0.06 ± 0.1971.14 ± 0.2071.24 ± 0.2011.31 ± 0.197
Medium Particles - Week 12 (n=139, 132, 132, 141)-0.26 ± 0.3110.72 ± 0.3191.60 ± 0.3201.61 ± 0.308
Medium Particles - Week 26 (n=147, 133, 141, 147)-0.26 ± 0.3130.95 ± 0.3291.19 ± 0.3201.30 ± 0.312
Small Particles - Week 12 (n=139, 132, 132, 141)0.50 ± 0.412-0.68 ± 0.423-2.65 ± 0.423-2.42 ± 0.410
Small Particles - Week 26 (n=147, 133, 141, 147)1.24 ± 0.412-0.28 ± 0.433-1.58 ± 0.421-1.63 ± 0.413
SecondaryChange From Baseline in Mean HDL Particle Size

Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean HDL particle size as a covariate.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · nm
Change From Baseline in Mean HDL Particle Size
nmAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Week 12 (n=139, 132, 132, 141)-0.02 ± 0.0240.09 ± 0.0250.17 ± 0.0250.15 ± 0.024
Week 26 (n=147, 133, 141, 147)-0.03 ± 0.0240.08 ± 0.0250.15 ± 0.0240.14 ± 0.024

Adverse events

Collected over Adverse events were collected from the time of informed consent until the end of the study, and from spontaneous reporting for 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alogliptin 25 mg—1/164 (0.6%)19/164 (11.6%)
Pioglitazone 30 mg—6/163 (3.7%)25/163 (15.3%)
Alogliptin 25 mg + Pioglitazone 30 mg—8/164 (4.9%)37/164 (22.6%)
Alogliptin 12.5 mg + Pioglitazone 30 mg—1/163 (0.6%)24/163 (14.7%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
Non-cardiac chest painGeneral disorders0/1641/1630/1640/163
HypertriglyceridaemiaMetabolism and nutrition disorders0/1641/1630/1640/163
Musculoskeletal painMusculoskeletal and connective tissue disorders0/1641/1630/1640/163
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1641/1630/1640/163
SyncopeNervous system disorders0/1641/1631/1640/163
Cerebral ischaemiaNervous system disorders0/1641/1630/1640/163
EndometriosisReproductive system and breast disorders0/1640/1630/1641/163
Acute myocardial infarctionCardiac disorders0/1640/1631/1640/163
Angina unstableCardiac disorders1/1640/1630/1640/163
Retinal detachmentEye disorders0/1640/1631/1640/163
Most frequent other events
Most frequent other events
EventAlogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mg
HeadacheNervous system disorders11/16411/16320/16414/163
Back painMusculoskeletal and connective tissue disorders1/1643/16310/1643/163
Oedema peripheralGeneral disorders2/1649/1634/1642/163
Urinary tract infectionInfections and infestations5/1644/1639/1646/163

Baseline characteristics

Age Continuous
Age Continuous(years)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
Mean52.6 ± 10.3851.5 ± 10.7252.8 ± 11.0153.5 ± 11.3752.6 ± 10.88
Age, Customized
Age, Customized(participants)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
< 65 years144143140130557
≥ 65 years2020243498
Sex: Female, Male
Sex: Female, Male(Participants)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
Female88739183335
Male76907381320
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
Hispanic or Latino63655862248
Not Hispanic or Latino10198106102407
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
American Indian or Alaska Native10001
Asian1415121657
Native Hawaiian or Other Pacific Islander00011
Black or African American8912938
White135130129132526
More than one race00000
Unknown or Not Reported6911632
Weight
Weight(kg)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
Mean86.72 ± 19.03385.53 ± 16.25485.39 ± 20.37484.38 ± 20.37885.50 ± 19.062
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
Mean31.61 ± 5.58730.87 ± 4.93831.32 ± 5.35430.71 ± 5.62131.13 ± 5.382
Duration of diabetes
Duration of diabetes(years)Alogliptin 25 mgPioglitazone 30 mgAlogliptin 25 mg + Pioglitazone 30 mgAlogliptin 12.5 mg + Pioglitazone 30 mgTotal
Mean3.23 ± 3.5593.20 ± 3.7393.05 ± 3.3283.36 ± 4.1663.21 ± 3.704
09

Study locations

161 sites
  • Columbiana, Alabama, United States
  • Hueytown, Alabama, United States
  • Huntsville, Alabama, United States
  • Northport, Alabama, United States
  • Tucson, Arizona, United States
  • Jonesboro, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Searcy, Arkansas, United States
  • Foothill Ranch, California, United States
  • Irvine, California, United States
  • Northridge, California, United States
  • San Diego, California, United States
  • San Mateo, California, United States
  • Santa Monica, California, United States
  • Jacksonville, Florida, United States
  • Melbourne, Florida, United States
  • Miami, Florida, United States
  • Port Charlotte, Florida, United States
  • Sebastian, Florida, United States
  • South Miami, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Barnesville, Georgia, United States
  • Columbus, Georgia, United States
  • Savannah, Georgia, United States
  • Chicago, Illinois, United States
  • Libertyville, Illinois, United States
  • South Bend, Indiana, United States
  • Bossier City, Louisiana, United States
  • Elkton, Maryland, United States
  • Prince Frederick, Maryland, United States
  • Towson, Maryland, United States
  • North Dartmouth, Massachusetts, United States
  • Bay City, Michigan, United States
  • Benzonia, Michigan, United States
  • Portage, Michigan, United States
  • St Clair Shores, Michigan, United States
  • Picayune, Mississippi, United States
  • St Louis, Missouri, United States
  • Billings, Montana, United States
  • Las Vegas, Nevada, United States
  • Elizabeth, New Jersey, United States
  • Hamilton, New Jersey, United States
  • Cicero, New York, United States
  • Charlotte, North Carolina, United States
  • Mooresville, North Carolina, United States
  • Northeast, North Dakota, United States
  • Franklin, Ohio, United States
  • Ashland, Oregon, United States
  • Altoona, Pennsylvania, United States
  • Fleetwood, Pennsylvania, United States
  • Harleysville, Pennsylvania, United States
  • Havertown, Pennsylvania, United States
  • Norristown, Pennsylvania, United States
  • Northern Cambria, Pennsylvania, United States
  • Penndel, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Florence, South Carolina, United States
  • Orangeburg, South Carolina, United States
  • Taylors, South Carolina, United States
  • Williamston, South Carolina, United States
  • Morristown, Tennessee, United States
  • Arlington, Texas, United States
  • Colleyville, Texas, United States
  • Conroe, Texas, United States
  • Corpus Christi, Texas, United States
  • Dallas, Texas, United States
  • Euless, Texas, United States
  • Fort Worth, Texas, United States
  • Garland, Texas, United States
  • Houston, Texas, United States
  • Katy, Texas, United States
  • San Antonio, Texas, United States
  • Seguin, Texas, United States
  • Sugarland, Texas, United States
  • Tomball, Texas, United States
  • Ogden, Utah, United States
  • Arlington, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Lewisburg, West Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Cap. Fed., Buenos Aires, Argentina
  • Chacabuco, Buenos Aires, Argentina
  • La Plata, Buenos Aires, Argentina
  • Mar del Plata, Buenos Aires, Argentina
  • Morón, Buenos Aires, Argentina
  • Córdoba, Argentina
  • Kingswood, New South Wales, Australia
  • Fitzroy, Victoria, Australia
  • Frankston, Victoria, Australia
  • Fortaleza, CE, Brazil
  • Goiás, GO, Brazil
  • Belém, PA, Brazil
  • Curitiba, PR, Brazil
  • Maringá, RP, Brazil
  • Marília, SP, Brazil
  • Mogi das Cruzes, SP, Brazil
  • Pleven, Bulgaria

Showing the first 100 of 161 sites across 23 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010 Nov;33(11):2406-8. doi: 10.2337/dc10-0159. Epub 2010 Aug 19. PubMed 20724648 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 5 years 1 month after primary completion. A results delay was requested in Jul 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2006
First posted
Nov 3, 2006
Start
Nov 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results delay requested
Jul 30, 2009
Results first posted
Mar 27, 2013
Last update
Mar 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00395512
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 3, 2006
Start date
Nov 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Mar 27, 2013
Last update
Mar 27, 2013

Study contacts

VP, Biological Sciences
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alogliptin · Pioglitazone

Start the discussion